Nanosonics Limited · ASX:NAN
Nanosonics — H1 2015 Earnings Presentation
21 slides from Nanosonics's earnings presentation, 2015
Slide 1: Leader in Infection Control Solutions - 2015 Half Year Results
LEADER IN INFECTION CONTROL SOLUTIONS Improving the safety of patients, clinics, their staff and the environment 2015 Half Year Results Investor Presentation
Slide 2: Disclaimer
Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs o
Slide 3: Corporate Mission
Corporate Mission We improve the safety of patients, clinics, their staff and the environment by transforming the way infection prevention practices are understood and conducted, and introducing innovative technologies that deliver improved standards of care. Johns Hopkins Photo Credit: American Nur
Slide 4: Company Overview
Company Overview Proprietary automated system for low temperature, high level disinfection (HLD) ® First product, trophon EPR, for HLD of ultrasound probes Approved for sale in most major markets including: US/Canada, ANZ, Europe, Singapore, HK, South Korea, Japan 118 staff across Australia,
Slide 5: Company Overview
Company Overview Key Corporate Data $1.80 Share price* $1.73 $1.70 $1.60 NAN ($) Shares on issue 264.4 million $1.50 $1.40 Market capitalisation* $457.3 million $1.30 Liquidity (30 day avg) 585,000 shares $1.20 $1.10 Cash (31 Dec 2014) $23.5 million $1.00 $0.90 Share register Founders/Related Partie
Slide 6: 2015 H1 Highlights
2015 H1 Highlights 44 of top 50 hospitals in US and more than 1,500 hospitals across North America using trophon EPR US installed base now in excess of 4,000 units Direct sales operations being established in North America alongside distribution partner, GE Healthcare (announced 6 February 201
Slide 7: 2015 H1 Financial Results
2015 H1 Financial Results 21.5 Sales $ million Sales Revenue up 48% on PCP H1 H2 14.9 14.3 to $14.3 million compared with 11.8 12.3 PCP of $9.7 million 10.5 7.2 14.3 9.7 5.1 4.4 FY12 FY13 FY14 FY15 H1 2012 2013 2014 2015 $1.2 Net profit of $1.2 million $0.3 $0.9 $1.2 compared to PCP loss of $3.5
Slide 8: 2015 H1 Financial results
2015 H1 Financial results FY15 FY14 FY13 Sales Revenue up 48% vs pcp $ million H1 H1 H2 FY14 H1 H2 FY13 Gross profit margin 64% vs pcp Sales Revenue 14.3 9.7 11.8 21.5 4.4 10.5 14.9 61.8% mainly due to: Gross Profit 9.2 6.0 7.9 13.9 3.0 5.5 8.5 o Increased proportion of high % 64% 62% 67% 65% 67
Slide 9: Strong Sales Growth in North America
Strong Sales Growth in North America FY15 H1 sales of $12.1 million up 51% vs Sales $17.7 pcp $ million H2 H1 $13.2 $9.7 $10.2 trophon EPR now represented in 44 of the top 50 hospitals and in more than 1,500 $6.5 $10.1 $12.1 hospitals in total $8.0 $3.7 $3.0 North American Installed base > 4,0
Slide 10: Direct Sales Operations Launched in North America
Direct Sales Operations Launched in North America Large North American opportunity ~ 40,000 units Opportunity to go: Broader across the 5,000+ hospitals Deeper within all relevant hospital departments (OB/Gyn, General imaging, Urology, Emergency care, Surgery etc. Leveraging existing North
Slide 11: European Highlights
European Highlights Sales $1.6 $ million H2 H1 $1.2 $1.0 $1.2 $0.4 $0.1 $0.2 $0.6 $0.1 $0.3 $0.2 2012 2013 2014 2015 FY15 H1 sales of $1.2 million up 109% pcp European distribution expanded into five new countries with distribution partner, Miele Professional New guidelines introduced reinforc
Slide 12: European Market Expanding
| European Market Expanding JVs NANa@sonics
Slide 13: New Ultrasound Probe Guidance Published in Wales
New Ultrasound Probe Guidance Published in Wales An automated, validated system is the preferred option The decontamination of transvaginal and transrectal probes should take place in the location they are being used, i.e. point of care For quality assurance/traceability purposes, a document s
Slide 14: Barts Health NHS
Barts Health NHS' NHS Trust Major nrObhon EPR Order Secured at Top London Hospital :
Slide 15: Continued Adoption in Australia and NZ
Continued Adoption in Australia and NZ trophon EPR now present in 566 hospitals across Australia & NZ 15
Slide 16: Japan Regulatory Approval Granted
Japan Regulatory Approval Granted 16
Slide 17: Clinical Studies Program Supporting Awareness and Adoption
Clinical Studies Program Supporting Awareness and Adoption European study showed trophon EPR to be significantly more effective than manual quaternary ammonium compound wipe disinfection. Study at The John Hopkins Hospital in the US showed need for disinfection of intracavity and surface probes (hea
Slide 18: New Corporate Headquarters to Support Growth Plans
New Corporate Headquarters to Support Growth Plans New Nanosonics Corporate Headquarters in Lane Cove, Sydney Previous Cochlear global headquarters Expands capacity and capability across all operations On track to move by end 2015 H2 18
Slide 19: Customer Focussed Innovation
Customer Focussed Innovation R&D strategy progressing for next generation trophon and pipeline opportunities Infection control remains a major healthcare issue Gaining insights on unmet needs from large customer base Progressing our technology innovation program across trophon and new applicat
Slide 20: Business Outlook – Positioned for Continued Growth
Business Outlook – Positioned for Continued Growth • Market fundamentals continue to strengthen – Increasing awareness of imaging related healthcare acquired infections – Supporting Guidelines for automated HLD solutions – Excellent clinical data and customer value propositions • Continuing to Expan
Slide 21: Thank You
nanoSonics UL’ Thank You